CBD Life Sciences Inc. (CBDL) Closes on LOI for Potential $8 Million Revenue Cannabis Dispensary
CBD Life Sciences (CBDL) has signed a Letter of Intent to acquire an interest in a New York cannabis dispensary from Market Wave Capital. The dispensary is expected to generate $8 million in annual revenue once operational, with an anticipated opening within six months, pending financing and state regulatory approvals. This strategic move positions CBDL in New York's cannabis market, projected to exceed $5 billion by 2027. The global marijuana dispensary market is forecasted to grow at a 25.5% CAGR, reaching $73.6 billion by 2030. The dispensary will serve as a platform for introducing CBDL's product lines and expanding into additional markets.
CBD Life Sciences (CBDL) ha firmato una Lettera di Intenti per acquisire un interesse in un dispensario di cannabis a New York da Market Wave Capital. Si prevede che il dispensario genererà 8 milioni di dollari di fatturato annuale una volta operativo, con un'apertura prevista entro sei mesi, in attesa di finanziamenti e approvazioni normative statali. Questa mossa strategica posiziona CBDL nel mercato della cannabis di New York, che si prevede supererà 5 miliardi di dollari entro il 2027. Si prevede che il mercato globale dei dispensari di marijuana crescerà a un CAGR del 25,5%, raggiungendo i 73,6 miliardi di dollari entro il 2030. Il dispensario servirà come piattaforma per introdurre le linee di prodotto di CBDL e per espandersi in ulteriori mercati.
CBD Life Sciences (CBDL) ha firmado una Carta de Intención para adquirir un interés en un dispensario de cannabis en Nueva York de Market Wave Capital. Se espera que el dispensario genere 8 millones de dólares en ingresos anuales una vez operativo, con una apertura anticipada en seis meses, sujeta a financiamiento y aprobaciones regulatorias estatales. Este movimiento estratégico posiciona a CBDL en el mercado de cannabis de Nueva York, que se proyecta que superará 5 mil millones de dólares para 2027. Se pronostica que el mercado global de dispensarios de marihuana crecerá a una tasa compuesta anual del 25,5%, alcanzando los 73,6 mil millones de dólares para 2030. El dispensario servirá como plataforma para introducir las líneas de productos de CBDL y expandirse a otros mercados.
CBD Life Sciences (CBDL)는 Market Wave Capital로부터 뉴욕의 대마초 약국에 대한 지분을 인수하기 위한 의향서를 체결했습니다. 이 약국은 운영이 시작되면 연간 800만 달러의 수익을 창출할 것으로 예상되며, 자금 조달 및 주 정부 규제 승인에 따라 6개월 이내에 개업할 예정입니다. 이 전략적 움직임은 CBDL을 뉴욕의 대마초 시장에 포지셔닝하며, 해당 시장은 2027년까지 50억 달러를 초과할 것으로 예상됩니다. 글로벌 대마초 약국 시장은 연평균 25.5% 성장률로 2030년까지 736억 달러에 이를 것으로 예상됩니다. 이 약국은 CBDL의 제품 라인을 소개하고 추가 시장으로 확장하는 플랫폼 역할을 할 것입니다.
CBD Life Sciences (CBDL) a signé une Lettre d'Intention pour acquérir un intérêt dans un dispensaire de cannabis à New York de Market Wave Capital. Le dispensaire devrait générer 8 millions de dollars de revenus annuels une fois opérationnel, avec une ouverture anticipée dans les six mois, sous réserve de financements et d'approbations réglementaires étatiques. Ce mouvement stratégique positionne CBDL sur le marché du cannabis de New York, dont les revenus devraient dépasser 5 milliards de dollars d'ici 2027. Le marché mondial des dispensaires de marijuana devrait croître à un taux de croissance annuel de 25,5%, atteignant 73,6 milliards de dollars d'ici 2030. Le dispensaire servira de plateforme pour introduire les lignes de produits de CBDL et s'étendre à d'autres marchés.
CBD Life Sciences (CBDL) hat einen Letter of Intent unterzeichnet, um ein Interesse an einem Cannabis-Dispensary in New York von Market Wave Capital zu erwerben. Es wird erwartet, dass das Dispensary einen Jahresumsatz von 8 Millionen Dollar generiert, sobald es betriebsbereit ist, mit einer möglichen Eröffnung innerhalb von sechs Monaten, abhängig von der Finanzierung und den staatlichen Genehmigungen. Dieser strategische Schritt positioniert CBDL im Cannabis-Markt von New York, der voraussichtlich bis 2027 5 Milliarden Dollar übersteigen wird. Der globale Markt für Marihuana-Dispensaries wird voraussichtlich mit einer jährlichen Wachstumsrate von 25,5% wachsen und bis 2030 73,6 Milliarden Dollar erreichen. Das Dispensary wird als Plattform dienen, um die Produktlinien von CBDL einzuführen und in zusätzliche Märkte zu expandieren.
- Expected annual revenue of $8 million from the new dispensary
- Strategic entry into New York's cannabis market, projected to reach $5 billion by 2027
- Opportunity for cross-promotional sales of existing CBDL products through the dispensary
- Acquisition completion depends on securing financing
- Subject to pending state regulatory approvals
- Six-month delay before potential revenue generation
With the New York cannabis market projected to surpass
SCOTTSDALE, AZ / ACCESSWIRE / November 19, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), a pioneering force in the CBD and cannabis industries, is proud to announce the signing of a pivotal Letter of Intent (LOI) to acquire an interest in a cannabis dispensary located in New York. The dispensary, purchased from Market Wave Capital, LLC, is expected to generate
A Game-Changing Move in a Booming Industry
The global marijuana dispensary market is on a meteoric rise, projected to grow at a compound annual growth rate (CAGR) of
"This acquisition is a monumental milestone for CBD Life Sciences and a testament to our aggressive growth strategy," said Lisa Nelson, President and CEO of CBDL. "The dispensary's location in New York positions us at the epicenter of one of the fastest-growing cannabis markets in the world. With projected revenues of
Why This Matters for CBDL and Its Investors
The dispensary's strategic location in New York provides immediate access to a cannabis market projected to exceed
For investors, this development underscores the company's ability to execute high-impact initiatives while navigating a highly competitive and regulated market. The acquisition not only bolsters CBDL's revenue potential but also establishes a foundation for future ventures in high-demand sectors, including recreational, medical, and hybrid cannabis markets.
Furthermore, the dispensary is expected to serve as a gateway for CBDL to introduce its own product lines into a retail setting, creating cross-promotional opportunities and fostering brand loyalty among a rapidly growing customer base.
Revenue, Growth, and a Vision for the Future
With potential revenues of
Market Diversification: The dispensary adds a robust revenue stream, complementing CBDL's existing portfolio of CBD products.
Future Expansion: Establishing a foothold in New York lays the groundwork for scaling operations to other states as cannabis legalization continues to gain momentum.
Enhanced Shareholder Value: The dispensary's profitability will drive returns for current shareholders while making CBDL an attractive investment for new stakeholders.
Strategic Significance
The acquisition reflects CBDL's forward-thinking approach to growth, as the company positions itself at the intersection of opportunity and innovation. By tapping into the New York cannabis market, CBDL is not just diversifying its portfolio but also creating synergies between its dispensary operations and its existing product lines, including pain creams, nano CBD coffee creamers, and more.
Additionally, the dispensary aligns with CBDL's mission to provide high-quality cannabis solutions while embracing consumer trends and regulatory changes. This move reinforces CBDL's standing as a company that is not only thriving in the present but also building for the future.
A Call to Shareholders and Future Investors
"This is only the beginning," added Nelson. "CBDL's strategic direction is clear: growth, innovation, and value creation. The dispensary will act as a springboard for broader ventures, and we are just getting started in leveraging the opportunities this industry offers."
CBDL invites shareholders and prospective investors to join us on this journey as we solidify our position as a leader in the cannabis and CBD industries. This acquisition underscores our commitment to seizing high-value opportunities and delivering long-term value to our shareholders. More updates to come!
About CBD Life Sciences Inc.
CBD Life Sciences Inc. (OTC PINK:CBDL) is a leading innovator in the CBD and cannabis industries, with a mission to enhance lives through premium-quality products and groundbreaking market strategies. The company's diverse portfolio and forward-thinking initiatives position it as a dynamic force in one of the most exciting and fast-growing industries in the world.
Follow our social media for the latest updates!
X: https://www.x.com/CBDL_StockOTC
Instagram: https://www.instagram.com/cbd.vault
IR Contact: cbdvaultaz@gmail.com
Forward-Looking Statements
Except for the historical information contained herein, the matters discussed in this press release are forward-looking statements. Actual results may differ materially from those described in forward-looking statements and are subject to risks and uncertainties. See CBD Life Sciences, Inc's, Inc.'s filings with OTC Markets, which may identify specific factors that may cause actual results or events to differ materially from those described in the forward-looking statements.
Safe Harbor Statement
This release includes forward-looking statements, which are based on certain assumptions and reflects management's current expectations. These forward-looking statements are subject to a number of risks and uncertainties that could cause actual results or events to differ materially from current expectations. Some of these factors include: general global economic conditions; general industry and market conditions, sector changes and growth rates; uncertainty as to whether our strategies and business plans will yield the expected benefits; increasing competition; availability and cost of capital; the ability to identify and develop and achieve commercial success; the level of expenditures necessary to maintain and improve the quality of services; changes in the economy; changes in laws and regulations, including codes and standards, intellectual property rights, and tax matters; or other matters not anticipated; our ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking ability to secure and maintain strategic relationships and distribution agreements. The Company disclaims any intention or obligation to update or revise any forward-looking statements.
Contact Information
Lisa Nelson
CEO
cbdvaultaz@gmail.com
4802091720
Related Images
|
SOURCE: CBD Life Sciences Inc.
View the original press release on accesswire.com
FAQ
What is the expected annual revenue from CBDL's new New York dispensary?
When will CBDL's New York cannabis dispensary open?
What is the projected size of New York's cannabis market by 2027?
Who is CBDL acquiring the New York dispensary from?
